New use of chloral hydrate for preparing pulmonary fibrosis disease

A technology for pulmonary fibrosis and chloral hydrate, which is applied in the field of medicine and can solve problems such as side effects, low immune function, and no effect on survival time.

Inactive Publication Date: 2008-11-26
吉林大学第二医院
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional treatment for this disease is long-term treatment with corticosteroids, but often only relieves symptoms without affecting survival time
However, long-term oral administration of a large amount of glucocorticoids will bring serious side effects. Patients may develop serious complications such as hypertension, diabetes, gastric ulcer, femoral head necrosis, and may also be complicated by severe lung or systemic infection due to low immune function. die

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0006] After the animals were perfused with bleomycin into the trachea, the animals were divided into five groups. The first four groups were given intraperitoneal injections of dexamethasone, curcumin, BCG polysaccharide nucleic acid, and chloral hydrate on the afternoon of the day of infusion. The model group was given intraperitoneal injection of normal saline. The animals were sacrificed on the 7th and 28th day after modeling, and the right lung was taken out and fixed, embedded and sliced ​​according to conventional pathological methods. The pathological sections were stained with HE and Maason respectively, and the degree of alveolitis (grade 0-+++) and pulmonary fibrosis (grade 0-+++) was determined according to the method provided by Szapielp. Results: 28 days after modeling, the model group: alveolitis +, fibrosis +++. Curcumin group: alveolitis 0, fibrosis ++. BCG polysaccharide nucleic acid group: alveolitis 0, fibrosis +. Dexamethasone group: alveolitis 0, fibro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new application that chloral hydrate is used for preparing drugs of pulmonary fibrosis diseases, which pertains to the medical field. The invention aims at providing the new application of the chloral hydrate, which particularly relates to the new application that the chloral hydrate is used for preparing the drugs of the pulmonary fibrosis diseases. The application of the chloral hydrate overcomes the difficulty of pulmonary fibrosis and causes the diseases that are similar to cancers to be controlled, thereby saving the lives of patients with the pulmonary fibrosis diseases.

Description

Technical field: [0001] The invention belongs to the field of medicine, and in particular relates to a new application of chloral hydrate. Background technique: [0002] Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by diffuse alveolitis and alveolar structural disorder, eventually leading to pulmonary fibrosis. At present, the etiology is not yet clear, and the disease generally continues to develop, and eventually dies due to respiratory failure. In recent years, its incidence has been on the rise. Most of the patients are middle-aged and elderly people, often at the age of 50 to 70. The onset is insidious. The main clinical manifestations are gradually aggravated dyspnea, accompanied by irritating dry cough. 2 to 3 years. The traditional treatment for this disease is long-term use of glucocorticoids, but often only relieves symptoms without affecting survival time. However, long-term oral administration of a large amount of glucocort...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/11A61P11/00
Inventor 张曼颖董春玲吴艳峰安继红
Owner 吉林大学第二医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap